Mode
Text Size
Log in / Sign up

Percutaneous Coronary Intervention

Part of Coronary Artery Disease

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Percutaneous Coronary Intervention

15 trials tracked for Percutaneous Coronary Intervention: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 154 citations.

15Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 4 Phase 2 1 Other / NA 7
  1. Phase 4 Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Completed · 154 cited
  2. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 76 cited
  3. Phase 3 Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) Completed · 25 cited
  4. Phase 4 Adenosine Contrast CorrELations in Evaluating RevAscularizaTION Completed
  5. Phase 4 Chewed Versus Integral Pill of Ticagrelor Completed
  6. Phase 3 A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Completed
Show 9 more trials
  1. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  2. Phase 2 Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56 Completed
  3. N/A Efficacy of Long Term Plavix Therapy Post Angioplasty Completed
  4. N/A Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE) Completed
  5. N/A Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure Completed
  6. N/A Cardiac Rehabilitation Peer Mentorship Completed
  7. N/A RAVE: Radial Artery Vascular Complication and Resource Utilization Completed
  8. N/A A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk Completed
  9. N/A GRX With ReMOTE: First in Human in India Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Percutaneous Coronary Intervention: what the trials found

Clinical trials have evaluated various pharmacological agents and interventions in the context of Percutaneous Coronary Intervention. Cangrelor was shown to significantly impact platelet reactivity as measured by VerifyNow PRU (63; 214, p<0.001) 2. Other established investigations included studies on Iopamidol 3, Ticagrelor [4, 7], and the P2Y12 inhibitor cangrelor 8.

Regarding anticoagulation and bleeding risks, rivaroxaban 2.5 mg was evaluated for clinically significant bleeding (15.7; 16.6; 24.0, p<0.001), while TIMI major and minor bleeding rates did not show statistically significant differences across groups (p=0.234 and p=0.144, respectively) 5. Dabigatran Etexilate 110mg was also studied, showing no significant difference in the time to death of undetermined cause or non-cardiovascular causes 6.

Recent results — preliminary, needs further review

  • Center-Based Cardiac Rehab is currently being evaluated as a new intervention 1.
  • Clopidogrel (not yet corroborated) 9
  • Wellframe (not yet corroborated) 10
  • RadAR EasyCLik plus ®-STF hemostatic pad (not yet corroborated) 11
  • Axiostat® (not yet corroborated) 12

For the clinician treating this condition

  • Cangrelor significantly affects platelet reactivity in patients undergoing intervention 2.
  • Rivaroxaban 2.5 mg is associated with clinically significant bleeding, though TIMI major and minor bleeding rates were not statistically different across cohorts 5.
  • Dabigatran Etexilate 110mg did not show significant differences in time to death of undetermined cause or non-cardiovascular causes 6.

AI synthesis of 10 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Coronary Artery Disease

Related studies from across the Coronary Artery Disease family.

Impact of Routine Functional Testing on Clinical Outcomes in Patients with Coronary Artery Disease
Cardiology RCT
Impact of Routine Functional Testing on Clinical Outcomes in Patients with Coronary Artery Disease Routine Stress Testing Does Not Reduce Heart Risk After Procedure
Routine functional testing at one year post-PCI did not improve clinical outcomes but led to a higher rate of invasive procedures.
Routine stress testing after heart procedures did not lower the risk of death or heart attacks, but it did lead to more invasive medical pro…
Higher Triglyceride-glucose index increases MACE risk in patients undergoing coronary artery bypass grafting
Diabetes & Endocrinology Meta-analysis
Higher Triglyceride-glucose index increases MACE risk in patients undergoing coronary artery bypass grafting Higher Triglyceride-Glucose Index Linked to Risks After Heart Surgery
This meta-analysis of 5,978 patients found that a higher Triglyceride-glucose index (TyG) is associated with a 62.4% higher hazard of MACE p…
A higher triglyceride-glucose index is linked to a higher risk of major heart events and death in patients following heart bypass surgery.
Acupuncture improves cardiac function and reduces MACE risk in patients after percutaneous coronary intervention
Cardiology Meta-analysis
Acupuncture improves cardiac function and reduces MACE risk in patients after percutaneous coronary intervention Acupuncture shows promise for heart function after coronary procedures
This meta-analysis of 759 patients suggests acupuncture may improve cardiac function and reduce major adverse cardiovascular events followin…
Acupuncture may improve heart function and walking distance for patients recovering from procedures to treat coronary artery disease.
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes
Cardiology Meta-analysis
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes Trial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients
This meta-analysis of 60,619 patients following percutaneous coronary intervention evaluates P2Y12 inhibitors using a Bayesian framework. Th…
A large analysis of over 60,000 patients suggests prasugrel may be more effective than clopidogrel for preventing major heart events after p…
Near-Styloid puncture improves first-attempt success and reduces access-site complications in coronary angiography
Radiology & Imaging RCT
Near-Styloid puncture improves first-attempt success and reduces access-site complications in coronary angiography Near-Styloid Puncture May Improve Success in Heart Procedures
This randomized controlled trial of 380 patients undergoing coronary angiography found that near-styloid puncture significantly improved fir…
A new puncture location for heart procedures may improve success rates and reduce complications like bruising or artery blockage.
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes
Diabetes & Endocrinology RCT
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes Trial shows clopidogrel alone reduces bleeding risk after heart procedures
This prespecified subgroup analysis of a randomized controlled trial involving 7758 patients with acute coronary syndromes found that clopid…
Patients with heart conditions may face fewer bleeding risks by switching to clopidogrel alone after a period of dual therapy.
Sirolimus-Eluting Balloon with Provisional Stenting for Small to Medium Coronary Arteries
Cardiology RCT
Sirolimus-Eluting Balloon with Provisional Stenting for Small to Medium Coronary Arteries Trial shows sirolimus-eluting balloon is comparable to standard stents
A randomized trial demonstrates that sirolimus-eluting balloon treatment is noninferior to systematic DES for target vessel failure in speci…
A new trial shows that a sirolimus-eluting balloon is as effective as standard stents for treating specific coronary artery blockages.
Evaluating Stepwise Dual Antiplatelet Therapy De-escalation in Patients Following Drug-Coated Balloon Angioplasty
Cardiology RCT
Evaluating Stepwise Dual Antiplatelet Therapy De-escalation in Patients Following Drug-Coated Balloon Angioplasty Trial Shows Stepwise DAPT De-escalation for Coronary Heart Disease
A prespecified subgroup analysis of the REC-CAGEFREE II trial evaluates the safety of DAPT de-escalation in ACS patients undergoing DCB-only…
New data shows that switching to a simpler blood thinner regimen may be as safe as standard treatment for patients with coronary artery dise…
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy
Cardiology RCT
Impact of Percutaneous Coronary Intervention Complexity on Ticagrelor or Prasugrel Monotherapy Efficacy Complex heart procedures do not change risks of certain medications
A post hoc analysis of the NEO-MINDSET trial evaluates if PCI complexity influences the safety and efficacy of potent P2Y inhibitor monother…
New analysis shows that complex heart procedures do not change the safety or effectiveness of specific blood-thinning medications.
Impact of Early Aspirin Withdrawal on Myocardial Infarction in Patients After PCI
Cardiology Meta-analysis
Impact of Early Aspirin Withdrawal on Myocardial Infarction in Patients After PCI Aspirin withdrawal shortly after heart procedures may increase heart attack risk
Early aspirin withdrawal within 30 days post-PCI significantly increases myocardial infarction risk, despite long-term reductions in bleedin…
Stopping aspirin within 30 days of a heart procedure may increase the risk of a heart attack in the first month.
Speckle-tracking echo detects coronary artery disease with 77% sensitivity and 75% specificity
Cardiology Meta-analysis
Speckle-tracking echo detects coronary artery disease with 77% sensitivity and 75% specificity Echocardiography Shows Moderate Accuracy for Detecting Coronary Artery Disease
This meta-analysis of 40 non-randomized studies (5,296 participants) found that speckle-tracking echocardiography (STE) has moderate diagnos…
A review of 40 studies shows that speckle-tracking echocardiography can help identify coronary artery disease with moderate accuracy.
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients
Cardiology RCT
Noninferiority of Ultra-thin Biodegradable Polymer Sirolimus Eluting Stents in Diabetic Patients New stent type shows promise for patients with diabetes and heart disease
A multicenter trial confirms that ultra-thin biodegradable polymer sirolimus-eluting stents meet noninferiority goals compared to durable po…
A new ultra-thin stent may offer a reliable option for people with both diabetes and complex heart disease.

Questions about Percutaneous Coronary Intervention

Can an AI model help doctors decide on my treatment plan for Percutaneous Coronary Intervention?

AI models are not yet proven to help doctors decide on PCI treatment plans; current research focuses on imaging and risk scores, not AI decision support.

Full answer →
Does a higher dose of heparin during elective PCI reduce bleeding complications?

Current evidence does not show that a higher heparin dose reduces bleeding; lower doses may be safer, but definitive results from the HD-PCI trial are pending.

Full answer →
Will stopping aspirin early after my Percutaneous Coronary Intervention cause a heart attack?

Stopping aspirin early after PCI may increase heart attack risk if no other antiplatelet is used, but switching to a P2Y12 inhibitor alone within 3 months does not significantly raise MI risk and reduces bleeding.

Full answer →
Can using intravascular imaging reduce my risk of major adverse events after PCI?

Yes, using intravascular imaging (IVUS or OCT) to guide PCI significantly reduces the risk of major adverse cardiovascular events compared to angiography alone.

Full answer →
Does having metabolic syndrome increase my risk of restenosis after Percutaneous Coronary Intervention?

Current evidence does not show a clear link between metabolic syndrome and higher restenosis risk after PCI, though related factors like insulin resistance may play a role.

Full answer →
See all 5 questions about Percutaneous Coronary Intervention →